<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>61(4)</volume><submitter>Kim DK</submitter><pubmed_abstract>&lt;h4>Purpose&lt;/h4>Despite the role of carbon monoxide in ameliorating ischemia-reperfusion injury (IRI), its use in the clinical setting is restricted owing to its toxicity. Herein, we investigated the &lt;i>in vivo&lt;/i> effects of carbon monoxide-releasing molecule-3 (CORM-3) on IRI.&lt;h4>Materials and methods&lt;/h4>Fifteen rats were equally and randomly divided into three groups: sham (right nephrectomy), control (right nephrectomy and left renal ischemia), and CORM-3 (right nephrectomy and CORM-3 injection before left renal ischemia). Kidney tissues and blood samples collected from sacrificed rats were evaluated to determine the renoprotective effect and mechanism of CORM-3.&lt;h4>Results&lt;/h4>Concentrations of serum creatinine and kidney injury molecule-1 in the CORM-3 group were significantly lower than in the control group after 75 minutes of IRI (1.2 vs. 2.4 mg/dL, p=0.01, and 292 vs. 550 pg/mL, p&lt;0.001, respectively). Furthermore, the CORM-3 group exhibited a higher portion of normal tubules and glomeruli. TUNEL staining revealed fewer apoptotic renal tubular cells in the CORM-3 group than in the control group. The expression of 960 genes in the CORM-3 group was also altered. Pretreatment with CORM-3 before renal IRI produced a significant renoprotective effect. Fifteen of the altered genes were found to be involved in the peroxisome proliferator-activated receptors signaling pathway, and the difference in the expression of these genes between the CORM-3 and control groups was statistically significant (p&lt;0.001).&lt;h4>Conclusions&lt;/h4>CORM-3 ameliorates IRI by decreasing apoptosis and may be a novel strategy for protection against renal warm IRI.</pubmed_abstract><journal>Investigative and clinical urology</journal><pagination>441-451</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC7329640</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Carbon monoxide-releasing molecule-3: Amelioration of renal ischemia reperfusion injury in a rat model.</pubmed_title><pmcid>PMC7329640</pmcid><pubmed_authors>Moon HS</pubmed_authors><pubmed_authors>Yoon YE</pubmed_authors><pubmed_authors>Choi HY</pubmed_authors><pubmed_authors>Lee J</pubmed_authors><pubmed_authors>Kim YT</pubmed_authors><pubmed_authors>Shin SJ</pubmed_authors><pubmed_authors>Park SY</pubmed_authors><pubmed_authors>Kim DK</pubmed_authors></additional><is_claimable>false</is_claimable><name>Carbon monoxide-releasing molecule-3: Amelioration of renal ischemia reperfusion injury in a rat model.</name><description>&lt;h4>Purpose&lt;/h4>Despite the role of carbon monoxide in ameliorating ischemia-reperfusion injury (IRI), its use in the clinical setting is restricted owing to its toxicity. Herein, we investigated the &lt;i>in vivo&lt;/i> effects of carbon monoxide-releasing molecule-3 (CORM-3) on IRI.&lt;h4>Materials and methods&lt;/h4>Fifteen rats were equally and randomly divided into three groups: sham (right nephrectomy), control (right nephrectomy and left renal ischemia), and CORM-3 (right nephrectomy and CORM-3 injection before left renal ischemia). Kidney tissues and blood samples collected from sacrificed rats were evaluated to determine the renoprotective effect and mechanism of CORM-3.&lt;h4>Results&lt;/h4>Concentrations of serum creatinine and kidney injury molecule-1 in the CORM-3 group were significantly lower than in the control group after 75 minutes of IRI (1.2 vs. 2.4 mg/dL, p=0.01, and 292 vs. 550 pg/mL, p&lt;0.001, respectively). Furthermore, the CORM-3 group exhibited a higher portion of normal tubules and glomeruli. TUNEL staining revealed fewer apoptotic renal tubular cells in the CORM-3 group than in the control group. The expression of 960 genes in the CORM-3 group was also altered. Pretreatment with CORM-3 before renal IRI produced a significant renoprotective effect. Fifteen of the altered genes were found to be involved in the peroxisome proliferator-activated receptors signaling pathway, and the difference in the expression of these genes between the CORM-3 and control groups was statistically significant (p&lt;0.001).&lt;h4>Conclusions&lt;/h4>CORM-3 ameliorates IRI by decreasing apoptosis and may be a novel strategy for protection against renal warm IRI.</description><dates><release>2020-01-01T00:00:00Z</release><publication>2020 Jul</publication><modification>2025-04-04T13:25:48.278Z</modification><creation>2025-04-04T13:25:48.278Z</creation></dates><accession>S-EPMC7329640</accession><cross_references><pubmed>32666002</pubmed><doi>10.4111/icu.2020.61.4.441</doi></cross_references></HashMap>